164 related articles for article (PubMed ID: 21277747)
1. Distributed lags time series analysis versus linear correlation analysis (Pearson's r) in identifying the relationship between antipseudomonal antibiotic consumption and the susceptibility of Pseudomonas aeruginosa isolates in a single Intensive Care Unit of a tertiary hospital.
Erdeljić V; Francetić I; Bošnjak Z; Budimir A; Kalenić S; Bielen L; Makar-Aušperger K; Likić R
Int J Antimicrob Agents; 2011 May; 37(5):467-71. PubMed ID: 21277747
[TBL] [Abstract][Full Text] [Related]
2. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
3. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H
Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of antibiotic resistance patterns of Pseudomonas aeruginosa and Acinetobacter spp. strains isolated from intensive care patients between 2000-2002 and 2003-2006 periods in Dokuz Eylul University Hospital, Izmir].
Yüce A; Yapar N; Eren Kutsoylu O
Mikrobiyol Bul; 2009 Apr; 43(2):195-202. PubMed ID: 19621603
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
Mutnick AH; Rhomberg PR; Sader HS; Jones RN
J Antimicrob Chemother; 2004 Feb; 53(2):290-6. PubMed ID: 14711839
[TBL] [Abstract][Full Text] [Related]
7. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
[TBL] [Abstract][Full Text] [Related]
9. [Pseudomonas aeruginosa: antimicrobial resistance in clinical isolates. Castellón 2004-2008].
Pardo Serrano FJ; Tirado Balaguer MD; García Zúñiga ED; Granados Ortega J; Campos Aznar A; Moreno Muñoz R
Rev Esp Quimioter; 2010 Mar; 23(1):20-6. PubMed ID: 20232020
[TBL] [Abstract][Full Text] [Related]
10. Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units.
Lewis GJ; Fang X; Gooch M; Cook PP
Infect Control Hosp Epidemiol; 2012 Apr; 33(4):368-73. PubMed ID: 22418632
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
12. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment.
Philippe E; Weiss M; Shultz JM; Yeomans F; Ehrenkranz NJ
Clin Perform Qual Health Care; 1999; 7(2):83-7. PubMed ID: 10747571
[TBL] [Abstract][Full Text] [Related]
13. Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis.
Baditoiu L; Axente C; Lungeanu D; Muntean D; Horhat F; Moldovan R; Hogea E; Bedreag O; Sandesc D; Licker M
Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):71. PubMed ID: 29132352
[TBL] [Abstract][Full Text] [Related]
14. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India.
Goel N; Wattal C; Oberoi JK; Raveendran R; Datta S; Prasad KJ
J Antimicrob Chemother; 2011 Jul; 66(7):1625-30. PubMed ID: 21586594
[TBL] [Abstract][Full Text] [Related]
15. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
18. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002.
Mohr JF; Jones A; Ostrosky-Zeichner L; Wanger A; Tillotson G
Int J Antimicrob Agents; 2004 Oct; 24(4):346-51. PubMed ID: 15380259
[TBL] [Abstract][Full Text] [Related]
19. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
Chin JN; Jones RN; Sader HS; Savage PB; Rybak MJ
J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa.
Al-Jasser AM; Elkhizzi NA
Saudi Med J; 2004 Jun; 25(6):780-4. PubMed ID: 15195211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]